The efficacy and role of Shafinamide Tablets (Siddaco) and its long-term safety and precautions

Safinamide tablets (Safinamide) is an oral reversible monoamine oxidaseB (MAO-B) inhibitor that also has sodium channel blockade and glutamate release. It has a regulatory effect and is mainly used to treat patients with Parkinson's disease (PD), especially for patients in the middle and late stages of treatment with "on-off" phenomenon or movement fluctuations caused by levodopa (L-dopa). By inhibiting dopamine degradation and regulating the release of excitatory neurotransmitters, safinamine can prolong the efficacy of levodopa, improve motor function, and improve non-motor symptoms related to Parkinson's disease, such as fatigue, depression, and mild cognitive decline.

In terms of efficacy and action, safinamine’s dual mechanism of action allows it to both enhance dopamine signaling and regulate over-excited glutamate neurotransmission. Clinical trials have shown that when used as adjuvant treatment with levodopa, safinamide can significantly prolong the patient's "on" state time, reduce the frequency of "off" state, and improve motor fluctuations and tremor. Long-term follow-up data show that patients UPDRSUPDRSafter taking safinide for 6 months to 2 years. span>(Unified Parkinson's Disease Rating Scale) motor scores were significantly improved, and quality of life (PDQ-39score) was also improved, indicating its sustained efficacy in the long-term management of Parkinson's disease.

Concerning the safety of long-term use, safinamide was generally well tolerated. Common adverse reactions include mild insomnia, headache, nausea, increased blood pressure, anxiety, etc. Most of them are mild to moderate and can be alleviated through symptomatic treatment. Compared with irreversible MAO-B inhibitors, the reversible nature of safinamine reduces the risk of serious drug interactions, especially when used in combination with levodopa or other dopaminergic drugs. In addition, clinical data show that long-term use of safinamide does not cause serious cardiovascular toxicity or irreversible neurological damage, showing high long-term safety.

In terms of precautions for use, patients should follow the doctor's advice and take the medication according to the dosage schedule when taking safinamine, usually once a day, with or without food. Please note that with otherMAOThe combined use of inhibitors, tricyclic antidepressants, and certain analgesics (such as normorphine) may increase the risk of hypertensive crisis or serotonin syndrome. Concurrent use should be avoided or the dosage should be adjusted under the guidance of a physician. For patients with hypertension, heart disease, or abnormal liver function, relevant indicators should be evaluated before medication, and blood pressure, liver function, and neurological symptoms should be monitored regularly during treatment. In addition, if patients experience serious adverse reactions such as significant increase in blood pressure, severe insomnia or mental disorder, they should seek medical treatment promptly and the doctor will evaluate whether to adjust the dosage or discontinue the drug.

In general, safinamine tablets can effectively improve the motor function and non-motor symptoms of patients with Parkinson's disease through the dual effects of MAO-B inhibition and glutamate regulation, and are particularly suitable as auxiliary treatment drugs for levodopa. Long-term use has shown sustained efficacy and high tolerability in clinical studies, with few serious adverse reactions, but individualized dose adjustment and regular monitoring are still required. Through standardized medication, reasonable follow-up and symptomatic treatment, safinamide can provide patients with safe, stable and sustained effective therapeutic effects in the long-term management of Parkinson's disease, improve quality of life and delay disease progression.

Reference materials:https://www.drugs.com/